 |
|
|
Mesuximide
|
|
| Systematic (IUPAC) name | |
| (RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione | |
| Identifiers | |
| CAS number | |
| ATC code | N03 |
| PubChem | |
| Chemical data | |
| Formula | C12H13NO2 |
| Mol. mass | 203.237 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic (demethylation and glucuronidation) |
| Half life | 1.4–2.6 hours (mesuximide) 28–38 hours (active metabolite) |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | Oral |
Mesuximide (or methsuximide) is an succinimide anticonvulsant medication. It is sold by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2]
References
- ^ Pfizer AG (2005). "Petinutin (Mésuximide)" (in French). Official Pfizer AG Website. http://www.pfizer.ch/internet/fr/home/products/central_nervous_system/epilepsy/petinutin_mesuximid.html. Retrieved on August 21 2006.
- ^ Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. http://www.pfizer.com/products/rx/rx_product_celontin.jsp. Retrieved on June 10 2008.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
